San Diego, CA (PRWEB) July 07, 2014
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Coumadin (Warfarin Sodium).
The FDA announced on July 1, that 6 lots of Coumadin (Warfarin Sodium) for Injection, 5 mg single-use vials, by Bristol-Myers Squibb, are recalled due to the presence of visible particulate matter.
If particulate metallic and non-metallic cellulose material is injected it can cause allergic and other serious, potentially life-threatening, reactions like embolization.
The affected lot numbers are: 201125, 201126, 201127, 201228, 201229, 201230 and they were distributed from November 2011 to January 2014.
Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Coumadin (Warfarin Sodium) and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”
As the FDA advises “Anyone that has Coumadin for Injection which is being recalled should stop use and distribution and contact Bristol-Myers Squibb’s recall vendor.” And the Agency adds “Bristol-Myers Squibb has issued recall communications to health care professionals and other customers involved and is arranging for return of all recalled products.”
AttorneyOne.com has further information on Coumadin (Warfarin Sodium) at the website including latest major drug and medical products law news.
Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/07/prweb11997162.htm